Sugi Predict

Sugi Predict / Compounds / SCHEMBL584513

SCHEMBL584513

SCHEMBL584513

CC(=O)OC(=O)c1ccco1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 12/20 0.56
▸ CES2 O00748 1/20 0.54
▸ CES1 P23141 1/20 0.54
▸ MAPT P10636 2/20 0.51
▸ TSHR P16473 1/20 0.51
▸ PTPN1 P18031 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ HSD17B10 Q99714 2/20 0.49
▸ PTPN2 P17706 1/20 0.49
▸ PTPN6 P29350 1/20 0.49
▸ PTPN11 Q06124 1/20 0.49
▸ MEN1 O00255 1/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28201534 0.98 KMT2A (0.54) KMT2ACES2CES1MAPTTSHR
SCHEMBL896787 0.87 CES2 (0.62) KMT2ACES2CES1MAPTTSHR
SCHEMBL11853792 0.85 KMT2A (0.53) KMT2ACES2CES1MAPTTSHR
SCHEMBL29120288 0.85 KMT2A (0.57) KMT2ACES2CES1MAPTTSHR
SCHEMBL7147963 0.84 CES2 (0.54) KMT2ACES2CES1MAPTTSHR
SCHEMBL28278771 0.83 KMT2A (0.58) KMT2ACES2CES1MAPTTSHR
SCHEMBL6338398 0.82 KMT2A (0.50) KMT2ACES2CES1MAPTTSHR
SCHEMBL7082818 0.81 KMT2A (0.51) KMT2ACES2CES1MAPTPTPN1
SCHEMBL28297982 0.80 KMT2A (0.55) KMT2ACES2CES1TSHRPTPN1
SCHEMBL363937 0.79 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11975023-B2 Methods for inhibiting anaerobic microorganisms LPOXY THERAPEUTICS, INC (US) 2024-05-07 — — US claimed
US-11944641-B2 Treatment of inflammatory bowel diseases through administration of enteric aerobization therapy LPOXY THERAPEUTICS, INC. (US) 2024-04-02 — — US claimed
US-11883428-B2 Enteric aerobization therapy LPOXY THERAPEUTICS, INC. (US) 2024-01-30 — — US claimed
WO-2006002031-A1 SUSTAINED RELEASE DOSAGE FORMS ANDRX CORPORATION (US) 2006-01-05 — — WO claimed
US-20050276849-A1 Sustained release dosage forms ANDRX CORPORATION 2005-12-15 — — US claimed
CN-88102048-A Make other pollutant also reduce to the method for minimum reduction content of nitrogen oxide — 1988-12-21 — — CN claimed
EP-4398876-A1 ENTERIC AEROBIZATION THERAPY Lpoxy Therapeutics, Inc. (US) 2024-07-17 — — EP disclosed
US-12036239-B2 Treatment of inflammatory bowel diseases through administration of enteric aerobization therapy LPOXY THERAPEUTICS, INC. (US) 2024-07-16 — — US disclosed
CN-118284405-A Intestinal aerobic therapy 卢普奥克西治疗公司 2024-07-02 — — CN disclosed
US-11975023-B2 Methods for inhibiting anaerobic microorganisms LPOXY THERAPEUTICS, INC (US) 2024-05-07 — — US disclosed
US-11944641-B2 Treatment of inflammatory bowel diseases through administration of enteric aerobization therapy LPOXY THERAPEUTICS, INC. (US) 2024-04-02 — — US disclosed
US-11883428-B2 Enteric aerobization therapy LPOXY THERAPEUTICS, INC. (US) 2024-01-30 — — US disclosed
US-20230277497-A1 ENTERIC AEROBIZATION THERAPY LPOXY THERAPEUTICS, INC. 2023-09-07 — — US disclosed
US-4160452-A Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina ALZA CORPORATION (US) 1979-07-10 — — US disclosed
US-4116241-A FOR CONTROLLED ORAL ADMINISTRATION OF DRUG ALZA CORPORATION (US) 1978-09-26 — — US disclosed
US-4077407-A POLYSACCHARIDES ALZA CORPORATION (US) 1978-03-07 — — US disclosed
US-4058122-A Osmotic system with laminated wall formed of different materials ALZA CORPORATION (US) 1977-11-15 — — US disclosed
US-4014334-A Laminated osmotic system for dispensing beneficial agent ALZA CORPORATION (US) 1977-03-29 — — US disclosed
US-4008719-A Osmotic system having laminar arrangement for programming delivery of active agent ALZA CORPORATION (US) 1977-02-22 — — US disclosed
US-3987069-A BORON PHOSPHATE CATALYST PETRO-TEX CHEMICAL CORPORATION (US) 1976-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11975023-B2 Methods for inhibiting anaerobic microorganisms SI, MB, ALPI KMT2A 2124/4885CES2 4399/4885CES1 2062/4885
US-12036239-B2 Treatment of inflammatory bowel diseases through administration of enteric aerobization therapy MB, NOD2, SI KMT2A 2908/4885CES2 4632/4885CES1 3013/4885
US-11883428-B2 Enteric aerobization therapy SI, MB, LPO KMT2A 3118/4885CES2 3885/4885CES1 1665/4885
US-11944641-B2 Treatment of inflammatory bowel diseases through administration of enteric aerobization therapy MB, NOD2, SI KMT2A 2908/4885CES2 4632/4885CES1 3013/4885
US-20230277497-A1 ENTERIC AEROBIZATION THERAPY SI, ALDOA, DERA KMT2A 2734/4885CES2 3581/4885CES1 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.